Browse by author
Lookup NU author(s): Professor Satnam Dlay,
Dr Gajanan Sherbet
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Oestrogen receptor (ER) expression is routinely measured in breast cancer management, but the clinical merits of measuring progesterone receptor (PR) expression have remained controversial. Hence the major objective of this study was to assess the potential of PR as a predictor of response to endocrine therapy. We report on analyses of the relative importance of ER and PR for predicting prognosis using robust multilayer perceptron artificial neural networks. Receptor determinations use immunohistochemical (IHC) methods or radioactive ligand binding assays (LBA). In view of the heterogeneity of intratumoral receptor distribution, we examined the relative merits of the IHC and LBA methods. Our analyses reveal a more significant correlation of IHCdetermined PR than ER with both nodal status and 5-year disease-free survival (DFS). In LBA, PR displayed higher correlation with survival and ER with nodal status. There was concordance of correlation of PR with DFS by both IHC and LBA. This study suggests a clear distinction between PR and ER, with PR displaying greater correlation than ER with disease progression and prognosis, and emphasizes the marked superiority of the IHC method over LBA. These findings may be valuable in the management of patients with breast cancer.
Author(s): Caronongan A, Venturini B, Canuti D, Dlay S, Naguib RNG, Sherbet GV
Publication type: Article
Publication status: Published
Journal: Anticancer Research
Print publication date: 01/04/2016
Acceptance date: 01/01/1900
ISSN (print): 0250-7005
Publisher: International Institute of Anticancer Research
PubMed id: 27069179